RxDoctor Payments Data

Peter Moenga, APRN

Psychiatric/Mental Health · Denton, TXNPI 1518325380

Payments from drug & device makers

$1,118in general payments, 2019–2025

Across 44 payments — averaging $25.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$520
  • Otsuka America Pharmaceutical, Inc.$298
  • Johnson & Johnson$144
  • Teva Pharmaceuticals USA, Inc.$76
  • E.r. Squibb & Sons, L.L.C.$41
  • Alkermes, Inc.$23
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$1,10499%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,118 in reported general payments places this provider in the 60th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$32,819
Medicare patients
81
Services billed
586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate111$315,126
IngrezzaValbenazine Tosylate29$216,859
Invega TrinzaPaliperidone Palmitate24$177,226
Abilify MaintenaAripiprazole40$91,170
RexultiBrexpiprazole33$47,468
VraylarCariprazine Hcl29$39,896
AristadaAripiprazole Lauroxil12$26,096
Clozapine105$12,443
TrintellixVortioxetine Hydrobromide22$10,168
Ziprasidone Hcl37$3,577
Quetiapine Fumarate ErQuetiapine Fumarate24$3,130
Duloxetine Hcl191$2,629
Quetiapine Fumarate196$2,537
Olanzapine126$1,995
Trazodone Hcl320$1,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$144$492,352135 claims
Neurocrine Biosciences, Inc.Ingrezza$520$216,85929 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$298$138,63873 claims
Alkermes, Inc.Aristada$23$26,09612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Denton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →